Antisense Technology

Patent Received for Antisense Oligonucleotides Oral Administration

Published in Cancer Weekly, February 3rd, 1997

Hybridon, Inc., Worcester, Massachusetts, announced the issuance of a U.S. Patent, which broadly claims methods of orally administering "hybrid" oligonucleotides which are comprised of regions of modified DNA and end-modified RNA (2'OMe substituted).

"Hybrid" oligonucleotides are a class of antisense agents which have improved stability in vivo and are covered broadly in an allowed U.S. Patent application. The patent stems from a scientific collaboration between Hybridon's chief scientific officer, Dr. Sudhir Agrawal, University of Alabama at Birmingham (UAB), Dr. Robert Diasio, and Dr. Ruiwen Zhang, UAB.

The researchers published back-to-back...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1997-02-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry